• Home
  • Study Details
Open

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

This study will evaluate the safety, tolerability, and anti-tumor activity of amivantamab SC as monotherapy and in addition to pembrolizumab or paclitaxel in participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Visit Availability

  • Standard business hours (M-F, 8-5)
  • Extended hours (M-F, early morning or evening)

Location

North Carolina (Statewide)

What will be asked of you

Depending on the Cohort you are assigned to, you may be asked to perform assessments, fill out questionnaires, etc.

In-person visits:
6 - 12+
Phone or online visits:
Potentially follow-up only
Total length of participation:
6 months - 2+ years

Looking for Healthy Volunteers

Requirements for healthy volunteers are different than for those with a specific condition. If you are interested in becoming a healthy volunteer for this study, use the below categories to determine if you are able to participate.

Able to participate:

  • 18 years or older
  • histologically or cytologically confirmed to have Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies

Not eligible if:

  • Under 18 years old

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Sid Sheth
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Head and Neck)

IRB Number

24-0434

ClinicalTrials.gov

NCT06385080

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research